Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson's disease
1. Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson's disease. We experienced that severe FOG was markedly improved by IV amantadine in the patients who had Parkinson's disease. But IV drug may have placebo effect. Therefore, We designed double blind, placebo controlled study to know whether IV amantadine is effective in the patient with dopaminergic-drug-resistant freezing of gait(FOG). 2. Cross over study design * Compare the change of FOGQ(freezing of gait questionaire) score from the baseline to IV amantadine and placebo drug * randomized assigned order of amantadine and placebo drug. * investigator of FOG: blinded to the order of drugs * each patient has IV drug for 2 days for each drug
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
20
IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
Seoul National University Hospital
Seoul, South Korea
RECRUITINGchange of FOGQ score
Time frame: 2 days for each drug
UPDRS and HY stage
Time frame: 2 days for each drug
side effect
Time frame: 2 days, 2 weeks after discharge
Patient global impression
Time frame: 2 days, 2 weeks after discharge
4*10m walk test
Time frame: 2 days for each drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.